Overview Technical Risk & rank Results Accounts Filings Guidance & governance
Filings
32 filings of ACUTAAS since December 2024.
presentation 9, transcript 8, board outcome 7, acquisition 3, credit rating 2, results 2
| Filed | Type | Subject | |
|---|---|---|---|
| 02 Nov 2026 | transcript Capex, Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about TranscriptAI summaryAcutaas Chemicals filed the transcript of its Q2 FY27 earnings conference call held on October 27, 2026. Naresh Patel (CMD) said Q2 revenue was Rs 4,369 million, up 42.7% year-on-year, and guided FY27 revenue growth to around 30% (from 25%) and EBITDA margin to 38%-40%. Management said the CDMO revenue target of Rs 1,000 crore is now expected in FY27, one year ahead of the FY28 goal, with a new target of Rs 2,000 crore by FY30. Bhavin Shah (CFO) reported Q2 EBITDA of Rs 1,760 million (40.3% margin) and PAT of Rs 1,231 million; H1 FY27 revenue was Rs 7,666 million and H1 EBITDA Rs 2,890 million. Management said H1 FY27 capex was Rs 1,239 million, full-year capex is expected around Rs 3,000 million, and the Specialty Chemicals segment revenue was Rs 349 million, down 20% year-on-year. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2026 | presentation Capex, Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about Investor PresentationAI summaryAcutaas Chemicals filed its investor presentation on Q2 and H1 FY27 financial results (quarter and half year ended September 30, 2026) under Regulation 30 of the SEBI LODR Regulations. Q2 FY27 revenue from operations was ₹4,369 million, up 42.7% YoY; EBITDA was ₹1,760 million (40.3% margin, up 84.6% YoY); PAT was ₹1,231 million (28.2% margin, up 71.4% YoY). H1 FY27 revenue was ₹7,666 million (up 49.3% YoY); EBITDA was ₹2,890 million (37.7% margin); PAT was ₹1,981 million (25.8% margin, up 71.0% YoY). Management (Mr. Naresh Patel, Executive Chairman and Managing Director) said it has revised FY27 revenue growth guidance upward from 25% to around 30% and raised EBITDA margin guidance to the 38-40% range. Management said the South Korea manufacturing facility was inaugurated ahead of schedule, producing high-purity chemicals for the semiconductor ecosystem; Specialty Chemicals softened due to commodity phase-outs and a change in ownership of a US customer. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 27 Oct 2026 | board outcome Results | Acutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.AI summaryAcutaas Chemicals Limited's board approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 on October 27, 2026, as recommended by the Audit Committee. Statutory auditors M/s. Maheshwari & Co. issued a limited review report with no matters noted that indicate misstatement. Standalone revenue from operations for the quarter ended September 30, 2026 was Rs. 33,008.85 lakhs (OCR reading; verify), and standalone profit for the period was approximately Rs. 8,573.65 lakhs (OCR reading; verify). Standalone total assets as at September 30, 2026 were Rs. 216,195.60 lakhs, against Rs. 193,545.42 lakhs as at March 31, 2026. The filing was made under Regulations 33 and 29 of the SEBI (LODR) Regulations, 2015. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Oct 2026 | acquisition Acquisition | Acutaas Chemicals Limited has informed the Exchange about AcquisitionAI summaryAcutaas Chemicals Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations on completion of an acquisition. The company completed the acquisition of 100% of the equity share capital of Enchem Ami Organics Private Limited, a step-down subsidiary, on October 17, 2026. The acquisition was made by transfer of 10,000 equity shares of face value Rs. 10/- each from Acutaas Chemicals Electrolytes Private Limited, a subsidiary of the company. Enchem Ami Organics Private Limited has become a direct wholly-owned subsidiary of the company. This follows an earlier intimation dated September 24, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Sep 2026 | acquisition Acquisition | Acutaas Chemicals Limited has informed the Exchange about AcquisitionAI summaryAcutaas Chemicals' board approved acquisition of 100% share capital of Enchem Ami Organics Private Limited (EAOPL), a step-down subsidiary, to make it a direct wholly owned subsidiary. Consideration is cash of Rs. 1,00,000 for 10,000 equity shares of Rs. 10 each, transferred from Acutaas Chemicals Electrolytes Private Limited at face value on an arm's length basis. EAOPL was incorporated on June 6, 2024, is engaged in specialty chemicals, and has nil turnover in FY2024-25 and FY2025-26. The acquisition is to be completed within one month, subject to applicable formalities. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jul 2026 | transcript Capex, Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about TranscriptAI summaryAcutaas Chemicals filed the transcript of its Q1 FY27 earnings conference call held on July 24, 2026, following results for the quarter ended June 30, 2026. Management reported revenue from operations of INR329.7 crores, up 59.1% Y-o-Y; EBITDA of INR113.1 crores at a 34.3% margin; and PAT of INR74.9 crores, up 70.4% Y-o-Y. CMD Naresh Patel said he remains confident of 25% revenue growth for the full year with stable margins, and said the battery chemicals plant has started commercial supply. Management said Q1 capex was INR56 crores, and that the Indichem plant capex is expected to be completed by the end of the quarter, with revenue from it expected from next financial year. CFO Bhavin Shah said the Specialty Chemicals margin is around 24% and the Pharma business margin is around 36%. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Jul 2026 | presentation Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about Investor PresentationAI summaryAcutaas Chemicals filed its investor presentation on Q1 FY27 (quarter ended June 30, 2026) results under Regulation 30. Management (Mr. Naresh Patel, Executive Chairman and Managing Director) said revenue from operations grew 59.1% YoY to Rs. 3,297 mn, EBITDA rose 122.1% YoY to Rs. 1,131 mn, and PAT rose 70.4% YoY to Rs. 750 mn. Q1 FY27 EBITDA margin was 34.3% and PAT margin 22.7%, versus 24.6% and 21.2% in Q1 FY26. Management said it remains confident of 25% revenue growth for the full year with stable margins. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Jul 2026 | board outcome Acquisition, Legal, Results | Acutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.AI summaryBoard of Directors approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 on July 24, 2026, as recommended by the Audit Committee; statutory auditor M/s. Maheshwari & Co. issued a limited review report. Consolidated revenue from operations for Q1 FY27 was Rs 32,967.48 lakhs, versus Rs 43,275.05 lakhs in the quarter ended March 31, 2026 and Rs 20,723.72 lakhs in the quarter ended June 30, 2025. Consolidated profit for the period was Rs 7,499.27 lakhs, versus Rs 13,428.37 lakhs in the quarter ended March 31, 2026 and Rs 4,401.05 lakhs in the quarter ended June 30, 2025. Basic EPS was Rs 9.07 for the quarter ended June 30, 2026 (not annualised). The company disclosed that its shareholding in subsidiary Acutaas Chemicals Electrolytes Private Limited was diluted from 100% to 90% effective May 19, 2026 through a preferential issue to A.R.Z Pharma Ltd., and that a CGST & CE Anti-Evasion Department inspection/search at its Surat facility (June 22-23, 2026) is not expected by management to have a material impact. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 16 May 2026 | presentation Capex, Results | Acutaas Chemicals Limited has informed the Exchange about Investor PresentationAI summaryAcutaas Chemicals Limited (formerly Ami Organics Limited) filed its Corporate Presentation with BSE and NSE dated May 16, 2026, for use at upcoming investor conferences/meets, per an earlier intimation dated May 14, 2026. The presentation shows FY26 revenue of ₹11,741 Mn from the Pharma Specialty segment (2 manufacturing facilities, 160+ customers), ₹157 Mn from Semiconductor (Baba Fine Chemicals, 55% subsidiary, plus Indichem Inc JV in South Korea), and no commercial revenue yet from Battery Chemicals (10+ products in pipeline, 5+ customers validated). Data in the presentation is as of March 31, 2026; the company reports 5 manufacturing facilities in total, with South Korea manufacturing capex ongoing. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 06 May 2026 | transcript Acquisition, Capex, Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about TranscriptAI summaryAcutaas Chemicals filed the transcript of its Q4 FY26 earnings conference call held on April 30, 2026. Management said FY26 revenue from operations was INR1,339.4 crores (up 33% Y-o-Y), EBITDA INR480.4 crores (2x) and PAT a record INR356.4 crores; Q4 revenue was INR432.8 crores (up 40.3% Y-o-Y) and Q4 PAT INR134.3 crores (up 114.1% Y-o-Y). Management guided to 25% revenue growth in FY27 and said it expects to maintain EBITDA margin at a similar level in the coming year, while noting near-term cost pressures from global supply chain disruption. Management said FY26 capex was INR195 crores, INR190 crores was invested in the South Korea JV Indichem Inc., and the R&D centre expansion is planned with 10x capacity; land acquisition opportunities are being evaluated. Management said battery chemicals and semiconductor businesses are expected to become self-sustaining growth engines by FY28, and net cash and cash equivalents were INR198.3 crores as on March 31, 2026. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Apr 2026 | presentation Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about Investor PresentationAI summaryAcutaas Chemicals filed its earnings investor presentation for Q4 and year ended March 31, 2026, under Regulation 30 of the SEBI LODR Regulations. Q4 FY26 revenue from operations was ₹4,328 million, up 40.3% YoY; EBITDA was ₹1,835 million (42.4% margin); PAT was ₹1,343 million (31.0% margin), up 114.1% YoY. FY26 revenue from operations was ₹13,394 million, up 33.0% YoY; EBITDA was ₹4,804 million (35.9% margin); PAT was ₹3,564 million (26.6% margin). Management (Mr. Naresh Patel, Executive Chairman and Managing Director) said it is confident of delivering 25% revenue growth in FY27. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Apr 2026 | board outcome Dividend / buy-back, Legal, Results | Acutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.AI summaryBoard of Acutaas Chemicals Limited, at its meeting held on April 30, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with auditor's reports. Board recommended a final dividend of Rs. 2.5 per equity share of Rs. 5 each (50%) on 8,18,71,122 equity shares for FY 2025-26, subject to shareholder approval at the ensuing AGM. Board appointed M/s Chirag Vallabhbhai Vekariya & Co. as Cost Auditors and M/s K. C Mehta & Co. LLP as Internal Auditors for FY 2026-27. Board identified Indichem INC as a Material Subsidiary of the Company based on the latest audited consolidated financial statements. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 03 Feb 2026 | transcript Acquisition, Capex, Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about TranscriptAI summaryAcutaas Chemicals filed the transcript of its Q3 FY26 earnings conference call held on January 28, 2026, following its results for the quarter and nine months ended December 31, 2025. Management said Q3 FY26 revenue from operations was INR393.2 crores, up 43% year-on-year, with PAT of INR106.2 crores (up 133.7%) and EBITDA margin of 38.3%. For the nine months of FY26, revenue from operations was INR906.6 crores (up 29.8%) and PAT was INR222.1 crores. Management revised FY26 revenue growth guidance to around 30% from 25%, and EBITDA margin guidance to 32%-35% from 28%-30%. Management said total FY26 capex is expected to be around INR220 crores versus INR250 crores guided earlier, and that about INR130 crores has been invested in the South Korea joint venture Indichem. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jan 2026 | presentation Capex, Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about Investor PresentationAI summaryAcutaas Chemicals filed its investor presentation under Regulation 30 on the Q3 FY26 and nine-month results ended December 31, 2025. Q3 FY26 revenue from operations was ₹3,932 Mn, up 43.0% YoY; EBITDA was ₹1,507 Mn (38.3% margin, up 119.4% YoY); PAT was ₹1,062 Mn (27.0% margin, up 133.7% YoY). 9MFY26 revenue was ₹9,066 Mn (up 29.8% YoY); 9MFY26 PAT was ₹2,221 Mn (up 127.3% YoY). Management (Executive Chairman and MD Naresh Patel) said it is revising its revenue growth guidance upward from 25% to approximately 30%, citing CDMO ramp-up and a healthy order book. Management said battery chemicals and semiconductor chemicals verticals are under active capital investment and are expected to operate as independent, self-sustaining growth engines over the next three years. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jan 2026 | board outcome Results | Acutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.AI summaryPages 7-8 are the auditor's limited review reports by Maheshwari & Co. on Acutaas Chemicals Limited's unaudited consolidated and standalone financial results for the quarter and nine months ended December 31, 2025. The reports state the auditor found nothing to suggest the statements were not prepared per Ind AS 34 and SEBI Listing Regulation 33, and they express no audit opinion. The consolidated review covers the parent, its subsidiaries, a partnership firm, a joint venture and step-down subsidiaries. The reports are dated January 28, 2026, and are addressed to the Board of Directors. The pages do not state the revenue, profit or other financial figures. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 04 Dec 2025 | credit rating Rating | Acutaas Chemicals Limited has informed the Exchange about Credit Rating- ReaffirmationAI summaryAcutaas Chemicals Limited filed under Regulation 30 of SEBI Listing Regulations to intimate a credit rating action dated December 04, 2025. CARE Ratings Limited reaffirmed the long term / short term bank facilities rating at CARE A+; Stable / CARE A1+. The rated bank facilities amount was enhanced to Rs. 135.00 crores from Rs. 125 crores. The rating was based on FY25 (audited) and H1FY26 (unaudited) operational and financial performance. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 24 Oct 2025 | transcript Capex, Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about TranscriptAI summaryAcutaas Chemicals filed the transcript of its Q2 & H1 FY26 earnings conference call held on October 17, 2025. Management said Q2 FY26 revenue from operations grew 24.1% year-on-year to INR306.2 crores, with EBITDA of INR95.3 crores (31.1% margin) and PAT of INR71.9 crores, up 91.3%. For H1 FY26, revenue was INR513.4 crores (up 21.3%), EBITDA INR146.2 crores and PAT INR115.9 crores. Management guided to around 25% revenue growth and an EBITDA margin of 28% to 30% for FY26, and said H1 FY26 capex was INR141 crores with about INR250 crores planned for FY26. Management said the Korea joint venture, Indichem, is expected to contribute to revenue from H2 FY27. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Oct 2025 | presentation Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about Investor PresentationAI summaryAcutaas Chemicals filed an investor presentation under Regulation 30 on financial results for the quarter and half year ended September 30, 2025 (Q2 FY26). Q2 FY26 revenue from operations was ₹3,062 million, up 24.1% YoY; EBITDA was ₹953 million (31.1% margin); PAT was ₹719 million (23.5% margin), up 91.3% YoY. H1 FY26 revenue from operations was ₹5,134 million and PAT was ₹1,159 million. Management (Mr. Naresh Patel, Executive Chairman and Managing Director) said it remains confident of delivering around 25% revenue growth for the full year. Management attributed Q2 growth to Advanced Pharmaceutical Intermediates, with stable contributions from Specialty Chemicals, and cited expansion into Battery Chemicals and Semiconductors. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 17 Oct 2025 | board outcome Results | Acutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.AI summaryAcutaas Chemicals Limited (formerly Ami Organics Limited) filed its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, approved by the Board on October 17, 2025. Standalone revenue from operations was Rs 30,519.34 lakh for the quarter ended September 30, 2025, against Rs 20,597.09 lakh in the June 2025 quarter and Rs 24,359.20 lakh in the September 2024 quarter. Standalone profit for the period was Rs 7,289.36 lakh for the quarter ended September 30, 2025, against Rs 4,454.62 lakh in the June 2025 quarter. Standalone basic earnings per share for the quarter were Rs 8.30 (not annualised). Standalone total equity stood at Rs 141,660.02 lakh as at September 30, 2025. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 05 Aug 2025 | transcript Acquisition, Capex, Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about TranscriptAI summaryAcutaas Chemicals filed the transcript of its Q1 FY26 earnings conference call held on July 30, 2025. Management said Q1 FY26 revenue from operations grew 17.3% year-on-year to INR207 crores, with gross margin at 53.2% and EBITDA margin at 24.6%, and PAT of INR44 crores versus INR14.7 crores in Q1 FY25. Management said capex for FY26 is expected to be around INR250 crores, funded from cash on hand, and that it reaffirmed confidence in 25% revenue growth in FY26. Management announced a joint venture named Indichem in South Korea, with an investment of approximately KRW30 billion for a 75% stake, for specialty chemicals used in chip production. Management said Ankleshwar Unit II was declared GMP compliant by Japan's PMDA, and that the electrolyte additive capex at Jhagadia is expected to be completed by Q3 FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jul 2025 | presentation Acquisition, Guidance, Results | Acutaas Chemicals Limited has informed the Exchange about Investor PresentationAI summaryAcutaas Chemicals filed an investor/earnings presentation for the quarter ended June 30, 2025 (Q1 FY26) under Regulation 30 of SEBI LODR. Q1 FY26 revenue from operations was Rs 2,072 million, up 17.3% year-on-year; EBITDA was Rs 509 million (24.6% margin) and PAT was Rs 440 million (21.2% margin), per the P&L statement. Management (Executive Chairman and Managing Director) said Q1 revenue growth was driven by the Pharmaceutical Intermediates business and that both pharma facilities are now PMDA GMP certified. Management said the company has entered a joint venture in South Korea aimed at key semiconductor markets. Management said it steps into FY26 with strong momentum and confidence to deliver 25% growth with improved margins. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 30 Jul 2025 | board outcome Results | Acutaas Chemicals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.AI summaryAcutaas Chemicals Limited's board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 on July 30, 2025, as recommended by the Audit Committee. Consolidated revenue from operations for Q1 FY26 was Rs 20,723.72 lakhs, versus Rs 30,848.34 lakhs in the March 31, 2025 quarter and Rs 17,667.09 lakhs in the June 30, 2024 quarter. Consolidated profit for the period was Rs 4,401.05 lakhs, versus Rs 6,271.61 lakhs in the March 31, 2025 quarter and Rs 1,468.97 lakhs in the June 30, 2024 quarter. Consolidated basic and diluted earnings per equity share (Rs 5 face value, not annualised) were Rs 5.41, versus Rs 7.80 in the March 31, 2025 quarter and Rs 1.83 in the June 30, 2024 quarter. Statutory auditors M/s. Maheshwari & Co. issued a limited review report, which the board took note of; the filing does not contain management commentary on outlook. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 23 Jul 2025 | acquisition Acquisition, Capex | Acutaas Chemicals Limited has informed the Exchange about AcquisitionAI summaryAcutaas Chemicals Limited (formerly Ami Organics Limited) filed an update under Regulation 30 on an investment in its wholly-owned subsidiary Acutaas Advance Material Limited (AAML). The company will subscribe to 30,48,780 equity shares of Rs 10 each at a premium of Rs 154 per share via rights issue, for up to Rs 49.99 crores (cash consideration), to be completed within one month. Further investment of up to Rs 150 crores by way of loan or equity, or a mix, is to be made in one or more tranches on or before March 31, 2026. AAML is engaged in specialty chemicals for the semiconductor industry; its turnover was Rs 30,00,000 in FY 2024-25 and Rs 73,35,000 in FY 2023-24. The transaction is with a related party (wholly-owned subsidiary), done at arm's length based on a registered valuer's report and approved by the Audit Committee. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 08 May 2025 | transcript Capex, Guidance, Management change, Results | Ami Organics Limited has informed the Exchange about TranscriptAI summaryAfi Ami Organics Limited filed the transcript of its Q4 FY25 earnings conference call held on May 2, 2025. Management said FY25 revenue from operations crossed INR1,006.9 crore (up 40.3% Y-o-Y), EBITDA was INR232.1 crore (up 80.6% Y-o-Y) and PAT was INR160.4 crore; Q4 FY25 revenue was INR308.5 crore (up 37.1% Y-o-Y) with PAT of INR62.7 crore. Management said FY25 capex was INR195 crore and planned capex for FY26 is around INR200 crore, to be funded through QIP proceeds and internal accruals. Management reaffirmed expectation of 25% revenue growth in FY26 and said the company decided to rename itself from Ami Organics Limited to Acutaas Chemicals Limited. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 May 2025 | presentation Guidance, Management change, Results | Ami Organics Limited has informed the Exchange about Investor PresentationAI summaryAmi Organics Limited filed its investor presentation on Q4 and FY25 results (year ended March 31, 2025) under Regulation 30 of the SEBI LODR Regulations. FY25 revenue from operations grew 40.3% YoY to Rs 10,069 mn; EBITDA rose 80.6% to Rs 2,321 mn; PAT rose 98.6% to Rs 1,604 mn (PAT adjusted for exceptional items). Q4FY25 revenue from operations grew 37.1% YoY to Rs 3,085 mn; EBITDA was Rs 850 mn (27.5% margin); PAT was Rs 627 mn (20.3% margin). Management (Executive Chairman and MD Naresh Patel) said FY25 surpassed Rs 1,000 crore in revenue, that the company is transitioning its name to Acutaas Chemicals Limited, and that it anticipates 25% revenue growth in FY26. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 02 May 2025 | board outcome Dividend / buy-back, Results | Ami Organics Limited has informed the Exchange regarding Outcome of Board Meeting held on May 02, 2025.AI summaryAmi Organics Limited filed the outcome of its board meeting held on May 02, 2025, approving audited standalone and consolidated financial results for the quarter and year ended March 31, 2025. The board recommended a final dividend of Rs. 1.5 per equity share (30% on Rs. 5 face value) on 8,18,68,922 equity shares for FY 2024-25, subject to shareholder approval at the AGM. The board appointed M/s Chirag Vallabhbhai Vekariya & Co. as Cost Auditors for FY 2025-26, effective May 2, 2025. The statutory auditor, Maheshwari & Co., issued an unmodified opinion on the annual consolidated financial results. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 21 Feb 2025 | bonus split Capex, Dividend / buy-back | Ami Organics Limited has informed the Exchange that the Board of Directors at its meeting held on February 21, 2025, has considered and approved subdivision of 40934461 equity shares of 10 each into 81868922 equity shares of 5 each.AI summaryAmi Organics Limited's board, at a meeting held on February 21, 2025, approved a 1:2 sub-division/split of its equity shares, from 1 equity share of Rs. 10 face value into 2 equity shares of Rs. 5 face value each. The board also approved altering Clause V of the Memorandum of Association, setting authorised share capital at Rs. 50,00,00,000 divided into 10,00,00,000 equity shares of Rs. 5 each. Post-split, issued, subscribed and paid-up equity shares would rise from 4,09,34,461 (Rs. 10 each) to 8,18,68,922 (Rs. 5 each). The split is subject to shareholder approval by postal ballot and regulatory approvals; the record date will be decided by the board after shareholder approval. The company expects completion tentatively within 3 months of shareholder approval, with the stated rationale being to enhance liquidity and encourage wider participation by small investors. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 01 Feb 2025 | transcript Capex, Guidance, Results | Ami Organics Limited has informed the Exchange about TranscriptAI summaryAfi Ami Organics Limited filed the transcript of its Q3 FY25 earnings conference call held on January 29, 2025, following Q3 and nine-month FY25 results. Management said Q3 FY25 revenue from operations was INR 275 crores, up 65.2% year-on-year and 11.5% sequentially, with EBITDA of INR 68.7 crores and PAT of INR 45.4 crores. For nine months FY25, revenue from operations was INR 698 crores, up 41.8% year-on-year, and PAT was INR 97.7 crores. Management revised FY25 growth guidance upward from 30% to 35%. Management said capex for nine months FY25 was INR 118 crores, and that Ankleshwar Block 2 has commercialized while Block 1 is expected by end of the quarter. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 29 Jan 2025 | results Results | Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024AI summaryAmi Organics Limited filed its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, approved by the Board on January 28, 2025, with an auditor's review report containing no modification. Standalone revenue from operations for the quarter ended December 31, 2024 was ₹21,004.42 lakh, against ₹16,169.89 lakh in the corresponding quarter of the prior year (Dec 31, 2023 column). Standalone profit after tax for the quarter ended December 31, 2024 was ₹4,505.3 lakh (figure as printed, text partly garbled), and for the nine months ended December 31, 2024 was ₹11,605.0 lakh (figure as printed, text partly garbled). Utilisation of preferential issue proceeds (₹9,909.99 lakh) was ₹2,976.71 lakh as of December 31, 2024; utilisation of QIP proceeds (₹39,999.99 lakh) was ₹30,416.08 lakh as of the same date. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jan 2025 | presentation Guidance, Results | Ami Organics Limited has informed the Exchange about Investor PresentationAI summaryInvestor presentation filed under Regulation 30 on Q3 and nine-month FY25 results (quarter and nine months ended December 31, 2024) of Ami Organics Limited. Q3FY25 revenue from operations grew 65.2% YoY to Rs. 2,750 mn; EBITDA Rs. 687 mn (25.0% margin); PAT Rs. 454 mn (16.5% margin). 9MFY25 revenue from operations was Rs. 6,984 mn, per management nearly equal to the previous full year's revenue. Management (Executive Chairman and MD Naresh Patel) said it has revised FY25 growth guidance upward from 30% to 35%, citing a strong ramp-up in the CDMO business. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 28 Jan 2025 | results Results | Ami Organics Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.AI summaryAmi Organics Limited filed unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2024, approved by the Board on January 28, 2025. Standalone revenue from operations was Rs 21,034.42 lakh for the quarter ended December 31, 2024, and Rs 68,567.32 lakh for the nine months ended December 31, 2024. Standalone net profit after tax was Rs 4,505.53 lakh for the quarter ended December 31, 2024 and Rs 9,669.99 lakh for the nine months (as printed in the extract). The statutory auditors, Maheshwari & Co., issued a limited review report with no modification. Unutilised proceeds were Rs 6,933.28 lakh from the preferential issue and Rs 9,583.91 lakh from the QIP, held in fixed deposits with banks. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
| 18 Dec 2024 | credit rating Rating | Ami Organics Limited has informed the Exchange about Credit Rating- RevisionAI summaryAmi Organics Limited filed an intimation under Regulation 30 of the SEBI Listing Regulations on the credit rating for its bank facilities. CARE Ratings Limited upgraded the long term/short term bank facilities to CARE A+; Stable/CARE A1+ from CARE A; Stable/CARE A1, per its letter dated December 17, 2024. Rated bank facilities of Rs. 125.00 crore, enhanced from Rs. 115 crore. The long term bank facilities rating of Rs. 0.00 crore was withdrawn. Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source. | NSE copy |
The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.